Business Wire10.02.20
Inteliquet, a provider of intelligent technology, insights, and services for optimizing clinical trials and research, has hired Jean Roberson, CPA, as chief financial officer (CFO). In her new role, she will report directly to Inteliquet President and Chief Operating Officer Marie E. Lamont.
“As demand for Inteliquet’s digital, data-driven clinical research solutions increases, we’re excited to have Jean’s multi-faceted expertise in raising venture and private capital funding, and developing strong business models,” said Lamont. “Jean is a true strategic financial partner and she adds a crucial skillset to our executive leadership team to help Inteliquet scale and reach its full potential.”
Most recently, Roberson was CFO at healthcare agency 2e Creative, where she helped lead its successful acquisition by Fishawack Health, a global healthcare communications group. She was responsible for establishing budgeting processes, reporting to the parent company, and integrating financial processes with the new ownership.
Before 2e Creative, Roberson was CFO and advisor to the CEOs of several software- and technology-based companies where she helped set strategic direction and empowered them to raise capital, grow revenue, and propel their operational success. From 1998 to 2019, she was CFO at several formative-stage companies, where she secured millions in venture capital and private equity funding and participated in several successful exits. From 1991 to 1998, she worked at Purina Mills Inc. She joined the company as internal auditor and progressed to director of Cash Management, assistant treasurer, and finally treasurer, reporting to the CFO. She began her career at Ernst and Young in St. Louis, planning full scope audits of public and private companies for GAAP and SEC compliance.
Roberson earned a bachelor of science degree in accounting from the University of Missouri, St. Louis.
“Inteliquet has tremendous opportunity to improve efficiency in clinical research through unique solutions that address many challenges that prevent novel therapies from getting to patients,” said Roberson. “This is an important mission, and I am excited to be part of an innovative company with a solid foundation of smart, experienced people. They work to help life sciences companies and healthcare organizations make clinical research more efficient, so new therapies can get to market more quickly, and patients and providers have more options.”
“As demand for Inteliquet’s digital, data-driven clinical research solutions increases, we’re excited to have Jean’s multi-faceted expertise in raising venture and private capital funding, and developing strong business models,” said Lamont. “Jean is a true strategic financial partner and she adds a crucial skillset to our executive leadership team to help Inteliquet scale and reach its full potential.”
Most recently, Roberson was CFO at healthcare agency 2e Creative, where she helped lead its successful acquisition by Fishawack Health, a global healthcare communications group. She was responsible for establishing budgeting processes, reporting to the parent company, and integrating financial processes with the new ownership.
Before 2e Creative, Roberson was CFO and advisor to the CEOs of several software- and technology-based companies where she helped set strategic direction and empowered them to raise capital, grow revenue, and propel their operational success. From 1998 to 2019, she was CFO at several formative-stage companies, where she secured millions in venture capital and private equity funding and participated in several successful exits. From 1991 to 1998, she worked at Purina Mills Inc. She joined the company as internal auditor and progressed to director of Cash Management, assistant treasurer, and finally treasurer, reporting to the CFO. She began her career at Ernst and Young in St. Louis, planning full scope audits of public and private companies for GAAP and SEC compliance.
Roberson earned a bachelor of science degree in accounting from the University of Missouri, St. Louis.
“Inteliquet has tremendous opportunity to improve efficiency in clinical research through unique solutions that address many challenges that prevent novel therapies from getting to patients,” said Roberson. “This is an important mission, and I am excited to be part of an innovative company with a solid foundation of smart, experienced people. They work to help life sciences companies and healthcare organizations make clinical research more efficient, so new therapies can get to market more quickly, and patients and providers have more options.”
